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Summary. Background: In an effort to improve interlaboratory
agreement in the monitoring of unfractionated heparin (UFH),
the College of American Pathologists (CAP) recommends that
the therapeutic range of the activated partial thromboplastin
time (APTT) be defined in each laboratory through correlation
with a direct measure of heparin activity such as the factor Xa
inhibition assay. Whether and to what extent this approach
enhances the interlaboratory agreement of UFH monitoring
has not been reported. Objectives: We conducted a cross-
validation study among four CAP-accredited coagulation
laboratories to compare the interlaboratory agreement of the
anti-FXa-correlated APTT with that of the traditional 1.5–2.5
times the midpoint of normal (1.5–2.5:control) method for
defining the therapeutic APTT range. Patients and methods:
APTT and FXa inhibition assays were performed in each
laboratory on plasma samples from 44 inpatients receiving
UFH. Results: Using the anti-FXa-correlation method, there
was agreement among all four laboratories as to whether a
sample was subtherapeutic, therapeutic or supratherapeutic in
seven (16%) patient samples. In contrast, consensus was
achieved in 23 (52%) samples when the 1.5–2.5:control method
was employed. Conclusions: The anti-FXa-correlation method
does not appear to enhance interlaboratory agreement in UFH
monitoring as compared with the traditional 1.5–2.5:control
method. Adoption of the anti-FXa-correlation method pro-
duces considerable disparity in UFH dosing decisions among
different centers, although the clinical impact of this disparity is
not known.
Keywords: activated partial thromboplastin time, anti-
factor Xa, factor Xa inhibition assay, unfractionated heparin.
Introduction
Intravenously administered unfractionated heparin (UFH) is a
mainstay of inpatient anticoagulation therapy for a variety of
clinical indications. Because the anticoagulant response to
UFH varies among individuals, the standard of care is to
monitor UFH and make dose adjustments on the basis of the
results of coagulation testing. Nevertheless, evidence for this
practice is weak and is based on a rabbit model of thrombosis
[1] and a post hoc subgroup analysis of an observational clinical
study [2], which demonstrated that UFH therapy prolonging
the activated partial thromboplastin time (APTT) to 1.5–2.5
times the midpoint of the control range (1.5–2.5:control) was
associated with a reduction in the risk of recurrent thrombosis.
On the basis of this evidence, use of theAPTT tomonitorUFH
with a therapeutic range of 1.5–2.5:control became standard
practice.
Thewisdom of a so-called fixed ratiomethod for defining the
therapeutic APTT range was later questioned when it was
appreciated that various APTT reagent–coagulometer combi-
nations differ, sometimes markedly, in their dose response to
UFH [3–8].With over 300 such combinations in use in different
laboratories by 1998 [9], interlaboratory variation in UFH
monitoring emerged as a major clinical concern.
To address this concern, the College of American Pathol-
ogists (CAP) [9] and the American College of Chest Physicians
(ACCP) [10] adopted guidelines recommending that clinical
laboratories define the therapeutic APTT range through
correlation with a direct assay of heparin activity such as
protamine titration or factor Xa inhibition (anti-FXa-correla-
tion method). Whether such an approach enhances interlab-
oratory agreement in UFH laboratory monitoring has not
been reported. We undertook a cross-validation study among
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four CAP-accredited laboratories to determine whether the
anti-FXa-correlation method improves upon the interlabora-




Samples from 44 adult inpatients at a single academic
medical center who were receiving UFH for a variety of
clinical indications were selected for analysis. All patients had
a normal APTT and prothrombin time prior to initiation of
UFH therapy, and none was on concomitant warfarin or
other medications reported to affect coagulation testing. The
study protocol was reviewed and approved by the institu-
tional review board of the center from which samples were
collected.
Laboratory assays
Venous blood was collected in 4.5-mL evacuated specimen
tubes (Becton Dickinson, Franklin Lakes, NJ, USA) con-
taining 3.2% sodium citrate. The samples were centrifuged at
1900 g for 10 min at 4 C. The plasma was then trans-
ferred to a microcentrifuge tube (Eppendorf, Hamburg,
Germany) and spun again at room temperature at 13000 g.
Aliquots of the plasma were transferred to clean poly-
propylene tubes (Fisher Scientific, Pittsburgh, PA, USA),
capped, and stored at ) 70 C. Frozen aliquots from each of
the 44 samples were sent on dry ice to specialized coagulation
laboratories at three other major academic medical centers.
APTT and FXa inhibition assays were performed on the
samples at each of the four laboratories, in accordance with
their standard operating procedures. The reagent–instrument
combinations employed by each laboratory are listed in
Table 1.
Simulated shipment
In an effort to simulate the shipping process, 10 samples were
packed and stored on dry ice for 24 h in laboratory A. APTT
and FXa inhibition assays were performed on each sample
before and after shipment, in order to evaluate the effect of
transport on test variability.
Statistical analysis
Laboratory results within and among laboratories were
compared by means of linear regression and tabulation of the
coefficient of determination (R2). Studentized residuals were
calculated to detect outliers. All analyses were carried out using
NCSS 2007 (NCSS; Kaysville, UT, USA).
Results
Intralaboratory correlation and derivation of therapeutic
ranges
Modest to poor correlation between the APTT and FXa
inhibition assays was observed in each of the four laboratories.
The coefficients of determination (R2) ranged from 0.1962 to
0.6964 (Fig. 1).When the single outlier most affecting theR2 at
each laboratory was excluded from the analysis, the R2
improved to 0.6296, 0.7636, 0.2708 and 0.6834 in laborato-
ries A, B, C and D, respectively.
In accordance with CAP guidelines, the anti-FXa-derived
therapeutic APTT range was defined by linear regression
corresponding to a range of anti-FXa activity of 0.3–
0.7 units mL)1. Therapeutic APTT ranges defined by both
this approach and the 1.5–2.5:control method are shown in
Table 2. In each laboratory, the range defined by the anti-FXa-
correlation method was broader than that defined using the
1.5–2.5:control method, and extended more than 29 s beyond
the upper limit of the 1.5–2.5:control range.
Interlaboratory correlations
Figure 2 depicts interlaboratory correlation for the FXa inhi-
bition assay for each pairwise comparison among the four
laboratories, and Fig. 3 shows the interlaboratory correlation
for the APTT assay for the same pairwise comparisons. The
FXa inhibition assay demonstrated superior interlaboratory
correlation to the APTT assay for all but one of the pairwise
comparisons (laboratory A vs. laboratory B), but the degree of
correlation for the FXa inhibition assay was nonetheless
Table 1 Reagents and instruments
Laboratory
APTT Factor Xa inhibition
Reagent Instrument Reagent Instrument
A MDA Platelin L* MDA-180* Stachrom Heparin Coag-A-Mate MTX II*
B HemosIL SynthASil ACL TOP HemosIL Heparin ACL TOP
C Actin FSL§ BCS§ Berichrome Heparin§ BCS§
D MDA Platelin L* MDA-180* Stachrom Heparin STA Compact
APTT, activated partial thromboplastin time.
*bioMérieux (Durham, NC, USA). Diagnostica Stago (Asnieres-sur-Seine, France). Instrumentation Laboratory (Paris, France). §Dade Behring
(Marburg, Germany).
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modest, with theR2 exceeding 0.8 in just one of the six pairwise
comparisons. Interestingly, although laboratories A and D
employed the same reagent in their FXa inhibition assay, and
the same reagent and instrument in theirAPTTassay (Table 1),
the correlation between them was nonetheless limited for both
the anti-FXa assay (Fig. 2C) and APTT assay (Fig. 3C).
Analysis by therapeutic range
Samples were segregated into therapeutic categories [i.e. below
therapeutic (BT), therapeutic (T), or above therapeutic (AT)]
on the basis of the laboratory-specific therapeutic APTT ranges
shown in Table 2. Interlaboratory agreement with respect to
therapeutic category for the 1.5–2.5:control method and the
anti-FXa-correlation method was assessed. When the 44
samples were classified by therapeutic category using the 1.5–
2.5:control method, 23 (52%) showed agreement among all
four laboratories, 17 (39%) showed agreement among three
laboratories, and four (9%) showed agreement between only
two laboratories. In contrast, when the samples were catego-
rized by the laboratory-specific anti-FXa-derived APTT range,
there was consensus among all four laboratories for just seven
(16%) samples, whereas 26 (59%) showed agreement among
three laboratories and 11 (25%) showed agreement among
only two laboratories. Three (7%) samples were found to be
simultaneously BT and AT in different laboratories with the
anti-FXa-correlation method, whereas two (5%) samples
showed this discrepancy with the 1.5–2.5:control method.
Because the intralaboratory correlation between the APTT
assay and FXa inhibition assay was particularly poor in
laboratory C (Fig. 1C), analysis by therapeutic range was
repeated with omission of this laboratorys results. When data
from laboratory C were excluded, the anti-FXa-correlation
method continued to show no apparent benefit over the 1.5–
2.5:control method with respect to interlaboratory agreement.
Specifically, therapeutic category agreement between laborato-
ries A, B and D was observed for 27 (61%) samples with the
1.5–2.5:control method and 25 (57%) samples with the anti-
FXa-correlation method.
The extent to which the poor interlaboratory agreement
observed with the anti-FXa-correlation method was due to
interlaboratory variation in the FXa inhibition assay itself was
examined. Using the CAPs recommended anti-FXa therapeu-
tic range for UFH of 0.3–0.7 units mL)1, samples were
categorized as BT (< 0.3 units mL)1), T (0.3–0.7 units mL)1),
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Fig. 1. Intralaboratory correlation between the activated partial throm-
boplastin time (APTT) and FXa inhibition assays. (A–D) Relationship
between the APTT and FXa inhibition assays (anti-FXa) in each labo-
ratory. The coefficient of determination (R2) is shown for each correlation.












A 21.8–32.5 40.7–67.9 45.4–106.0
B 27.0–37.1 48.1–80.1 53.6–125.0
C 23.3–30.2 40.1–66.9 83.2–194.3
D 24.0–37.0 45.8–76.3 61.7–105.4
The 1.5–2.5:control method ranges are derived by multiplying the
midpoint of the APTT reference range by 1.5 and 2.5, respectively. The
anti-FXa-correlation method ranges are derived from the linear
regressions shown in Fig. 1, such that the lower and upper limits of the
therapeutic range correspond to 0.3 and 0.7 anti-FXa units mL)1,
respectively.
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showed therapeutic range agreement among all four laborato-
ries, 11 (25%) showed agreement among three laboratories,
and five (11%) showed agreement among only two laborato-
ries. None of the 44 samples was found to be simultaneously
AT and BT in different laboratories. When the data from
laboratory C were excluded, therapeutic range agreement was
observed among laboratories A, B and D for 35 (80%)
samples.
Shipment analysis
In order to determine whether transport and shipping condi-
tions contributed to the observed variation among laboratories
in the APTT and FXa inhibition assays, a simulated shipment
experiment was performed. No significant differences in APTT
or anti-FXa values were seen when samples analyzed before
and after simulated shipment were compared (data not shown).
Discussion
Since 1998, the CAP has mandated that the therapeutic APTT
range for UFH be defined in each laboratory through
correlation with a direct measure of heparin activity such as
the FXa inhibition assay [9], in part to improve upon the
substantial interlaboratory variation observed with the
traditional 1.5–2.5:control method. Whether the anti-FXa-
correlation method satisfies this intent has not been reported.
We performed a cross-validation study among four CAP-
accredited specialized coagulation laboratories to compare the
interlaboratory variation of the anti-FXa-correlation method
with that of the traditional 1.5–2.5:control method.
In our small study, we observed significant interlaboratory
variation in the anti-FXa-correlation method with respect to
therapeutic range. With this method, there was consensus
among the four laboratories as to whether a patient was BT, T
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Fig. 2. Interlaboratory correlation for the FXa inhibition assay. (A–F) Pairwise correlations for the FXa inhibition assay (anti-FXa) among each of the
four laboratories. The coefficient of determination (R2) is shown for each comparison.
Interlaboratory agreement in heparin monitoring 83
 2008 International Society on Thrombosis and Haemostasis
or AT in only 16% of samples. In contrast, consensus was
achieved in 52% of samples with the 1.5–2.5:control method.
When consensus was redefined as therapeutic range agreement
among at least three laboratories, it was achieved in 75% of
samples with the anti-FXa-correlation method and in 91% of
samples with the 1.5–2.5:control method. The anti-FXa-
correlation method remained non-superior to the 1.5–2.5:con-
trol method with respect to interlaboratory consensus (57% vs.
61%) when the poorly correlated data from laboratory C
(Fig. 1C) were excluded from the analysis.
By definition, the validity of the anti-FXa-correlation
method relies on two relationships – the intralaboratory
correlation between the FXa inhibition assay and the APTT
assay, and the interlaboratory correlation for the FXa
inhibition assay. In our study, correlation for both of these
relationships was modest. Consistent with previous analyses
[11–13], we observed R2 values of 0.5459–0.6964 for the
intralaboratory correlation between the anti-FXa and APTT
assays in laboratories A, B and D (Fig. 1). However,
laboratory C demonstrated an R2 for this relationship of
0.1962, substantially lower than what has been reported
previously. Although assessments of correlation in the
literature may be mildly inflated by publication bias, the
very poor correlation between the APTT and anti-FXa
assays in laboratory C raises concern about an unidentified
technical problem with one or both of the assays. For this
reason, therapeutic range analyses were performed both with
and without the data from laboratory C as described above.
Although the poor intralaboratory correlation observed in
laboratory C constitutes a limitation of our study, it also
highlights the technical challenges associated with the APTT
and anti-FXa assays, an issue of real-world relevance to
the coagulation laboratories in which these assays are
performed.
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Fig. 3. Interlaboratory correlation for the activated partial thromboplastin time (APTT). (A–F) Pairwise correlations for the APTT assay among each of
the four laboratories. The coefficient of determination (R2) is shown for each comparison.
84 A. Cuker et al
 2008 International Society on Thrombosis and Haemostasis
Modest interlaboratory correlation for the FXa inhibition
assay was also observed, with the R2 for the pairwise
comparisons ranging from 0.4395 to 0.8009 (Fig. 2). These
results are consistent with previously published reports, which,
much as is observed with the APTT assay, show variation in
the responsiveness of the FXa inhibition assay depending on
the choice of reagent and instrumentation [14–16]. Interest-
ingly, the correlation for the anti-FXa assay between labora-
tories A and D was limited (Fig. 2C), despite the use of a
common reagent (Table 1). This may underscore the impor-
tance of instrument, as well as reagent, in the responsiveness of
the anti-FXa assay to UFH [15]. Despite the use of a common
reagent and a common coagulometer, limited correlation for
the APTT assay between these centers (Fig. 3C) was also
observed. This may reflect the laboratories use of different
reagent lots in their APTT assays, a variable that has also been
reported to influence the response of the APTT to UFH [8].
Issues related to specimen storage and transport have been
demonstrated to affect the APTT and FXa inhibition assays
[17,18], and represent another potential source of interlabora-
tory variation in our study. To address this possibility, a
simulated shipment experiment was carried out; this showed no
significant difference between the pre-shipment and post-
shipment APTT or anti-FXa, suggesting that the interlabora-
tory variation observed in our study is not attributable to
preanalytical transport and shipping variables.
In spite of the modest interlaboratory correlation observed
with the FXa inhibition assay, it showed somewhat better
interlaboratory agreement than either the anti-FXa-correlation
method or the 1.5–2.5:control method. Using the FXa
inhibition assay, therapeutic range consensus among all four
and among at least three laboratories was observed for 64%
and 89% of samples, respectively. When the data from
laboratory C were excluded, therapeutic range agreement
among laboratories A, B and D was observed for 80% of
samples. Furthermore, whereas several patient samples were
found to be simultaneouslyAT andBT in different laboratories
by both the anti-FXa-correlation method and the 1.5–2.5:con-
trol method, this striking discrepancy was not observed with
the FXa inhibition assay itself.
These results suggest that the FXa inhibition assay may
prove clinically superior to both the anti-FXa-correlation
method and the 1.5–2.5:control method in the monitoring of
UFH. However, enthusiasm for the FXa inhibition assay for
this purpose has been tempered, both because of its greater cost
than the APTT assay and because of clinicians greater
familiarity and comfort with the APTT assay. Furthermore,
few clinical data are available to support use of the FXa
inhibition assay in UFHmonitoring. In a trial by Levine et al.,
patients with acute venous thromboembolism requiring large
daily doses of UFH randomized to monitoring by either direct
anti-FXa level or protamine titration-correlated APTT showed
roughly equal rates of recurrent thrombosis and bleeding [19].
Because this study was performed within a single center,
interlaboratory variation in the monitoring methods could not
be assessed. To our knowledge, no other randomized trials of
UFH monitoring have been performed, and opinions on the
clinical value of various monitoring techniques have been
derived largely from observational and laboratory-based data.
Clearly, randomized, controlled, multicenter clinical trials
would be necessary to determine the optimal approach for
UFH monitoring.
As UFH enters its eighth decade of clinical use [20], the
optimal method for its monitoring remains unknown. Our
small study suggests that the anti-FXa-correlation method,
recommended by the CAP and ACCP for the purpose of
improving upon the poor interlaboratory agreement observed
with the 1.5–2.5:control method, does not appear to satisfy this
intent. Further multicenter cooperative studies are required to
confirm these findings. On the basis of our data, adoption of
the anti-FXa-correlationmethod would appear to lead to great
disparity in UFH dosing decisions among different centers.
The clinical impact of this disparity is unknown and also
warrants further investigation.
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